LetterLetter
Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis
Doron Rimar, Itzhak Rosner and Gleb Slobodin
The Journal of Rheumatology February 2021, 48 (2) 304-305; DOI: https://doi.org/10.3899/jrheum.200484
Doron Rimar
1Rheumatology Unit, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
MDItzhak Rosner
1Rheumatology Unit, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
Roles: Professor
Gleb Slobodin
1Rheumatology Unit, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
Roles: Professor
REFERENCES
- 1.↵
- Herrick AL,
- Peytrignet S,
- Lunt M,
- Pan X,
- Hesselstrand R,
- Mouthon L, et al.
- 2.
- 3.↵
- Volkmann ER,
- Tashkin DP,
- Sim M,
- Li N,
- Goldmuntz E,
- Keyes-Elstein L, et al; SLS I and SLS II study groups
- 4.↵
- Tashkin DP,
- Roth MD,
- Clements PJ,
- Furst DE,
- Khanna D,
- Kleerup EC, et al; Sclerodema Lung Study II Investigators
- 5.↵
- Burt RK,
- Shah SJ,
- Dill K,
- Grant T,
- Gheorghiade M,
- Schroeder J, et al.
- 6.↵
- Van Laar JM,
- Farge D,
- Sont JK,
- Naraghi K,
- Marjanovic Z,
- Larghero J, et al; EBMT/EULAR Scleroderma Study Group
- 7.↵
- 8.↵
- 9.↵
- Fraticelli P,
- Fischetti C,
- Salaffi F,
- Carotti M,
- Mattioli M,
- Pomponio G, et al.
- 10.↵
- Pope JE.
In this issue
The Journal of Rheumatology
Vol. 48, Issue 2
1 Feb 2021
Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis
Doron Rimar, Itzhak Rosner, Gleb Slobodin
The Journal of Rheumatology Feb 2021, 48 (2) 304-305; DOI: 10.3899/jrheum.200484